<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> has been shown to play a pivotal role in the growth and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Numerous in vitro and translational research studies have implicated a role for <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in the pathogenesis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Although the role of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> inhibitors in the treatment of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> has evolved significantly over the past 5 years, their role in the treatment of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> such as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> remains investigational </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treatment historically has been challenging, but the US Food and Drug Administration in the past 4 years has approved the hypomethylating agents 5-<z:chebi fb="0" ids="2038">azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> and the immunomodulatory agent lenalidomide for the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>These approvals highlight recent successes in identifying and targeting pathobiologic abnormalities that contribute to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Drugs such as lenalidomide and the first-generation analogue from which it was derived, thalidomide, exert multiple mechanisms of action but partially act via inhibition of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Over the next 5 to 10 years, preclinical and clinical evaluation of agents with more strictly defined antiangiogenic activity, such as inhibitors of vascular endothelial growth factor, or agents with partial antiangiogenesis activity, such as multitargeted <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi>, will ultimately help define the utility of angiogenic blockade in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>